Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 5,502 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Completed Phase 3 Interventional

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

NCT06973577
View directory record Official record
Conditions
ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions
Centanafadine, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Results available

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Beverly Hills, California • Sherman Oaks, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
Itacitinib, Immune effector cell therapy, Placebo, Yescarta
Drug · Biological
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

NCT05849922
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Ocala, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251745
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

NCT04322539
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Colon Cancer
Interventions
Fruquintinib, Placebo
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

NCT01510769
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Lesinurad, Placebo, Febuxostat
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
99
States / cities
Birmingham, Alabama • Goodyear, Arizona • Peoria, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
View directory record Official record
Conditions
Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders, Postoperative Delirium
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 23, 2026, 1:02 PM EDT
Terminated Phase 4 Interventional Results available

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

NCT00366301
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine injection, metformin, Placebo pill
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

NCT03150719
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tezacaftor/Ivacaftor, Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 23, 2026, 1:02 PM EDT
Terminated Phase 4 Interventional Results available

Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study

NCT01275339
View directory record Official record
Conditions
Aortic Stenosis, LV Remodeling, Hypertrophy
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

NCT01575873
View directory record Official record
Conditions
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Interventions
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

NCT02796677
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
85
States / cities
Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

NCT00285012
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, Varenicline Tartarate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2010 · Synced Oct 23, 2026, 1:02 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

NCT06248229
View directory record Official record
Conditions
Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions
Dyanavel XR, Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 23, 2026, 1:02 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis

NCT00361439
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Tinnitus With Migraine Medications

NCT04404439
View directory record Official record
Conditions
Tinnitus, Subjective, Tinnitus
Interventions
Nortriptyline + Topiramate, Verapamil + Paroxetine, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
25 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

NCT02430870
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TAK-648, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Anaheim, California • Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

NCT01739595
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Rancho Cucamonga, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

NCT06024239
View directory record Official record
Conditions
Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 23, 2026, 1:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

NCT01561430
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 23, 2026, 1:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Atenolol, Nebivolol, Propranolol, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 23, 2026, 1:02 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
15,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
357
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 1:02 PM EDT